Evidence map›Paper›PMID 40641044›Full record

ArticleBriefings in bioinformatics2025

Assessing Random Forest self-reproducibility for optimal short biomarker signature discovery.

Ahmed Debit, Christophe Poulet, Claire Josse, Guy Jerusalem, Chloe-Agathe Azencott, Vincent Bours, Kristel Van Steen

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmed DebitLaboratory of Human Genetics, GIGA Institute, University of Liege (ULiege), Avenue Hippocrate 1/11, 4000 Liege, Belgium.ORCID 0000-0002-2662-0772
Christophe PouletDepartment of Rheumatology, GIGA Institute, University Hospital of Liege (CHULiege), University of Liege (ULiege), Avenue Hippocrate 1/11, 4000 Liege, Belgium.
Claire JosseLaboratory of Human Genetics, GIGA Institute, University of Liege (ULiege), Avenue Hippocrate 1/11, 4000 Liege, Belgium.
Guy JerusalemOncology Department, University Hospital of Liege (CHULiege), University of Liege (ULiege), Avenue de l'Hopital 1, 4000 Liege, Belgium.
Chloe-Agathe AzencottMines Paris, PSL Research University, CBIO-Centre for Computational Biology, 60 boulevard Saint-Michel, F-75006 Paris, France.
Vincent BoursLaboratory of Human Genetics, GIGA Institute, University of Liege (ULiege), Avenue Hippocrate 1/11, 4000 Liege, Belgium.
Kristel Van SteenBIO3, GIGA Institute, University of Liege (ULiege), Avenue Hippocrate 1/11, 4000 Liege, Belgium.

Funding

European Union's Horizon 2020 research and innovation programMarie Skłodowska-Curie 813533Région Wallonne within the project WalInnov-NACATS 1610125
6 · The paper itself

Abstract

Biomarker signature discovery remains the main path to developing clinical diagnostic tools when the biological knowledge on pathology is weak. Shortest signatures are often preferred to reduce the cost of the diagnostic. The ability to find the best and shortest signature relies on the robustness of the models that can be built on such a set of molecules. The classification algorithm that will be used is often selected based on the average Area Under the Curve (AUC) performance of its models. However, it is not guaranteed that an algorithm with a large AUC distribution will keep a stable performance when facing data. Here, we propose two AUC-derived hyper-stability scores, the Hyper-stability Resampling Sensitive (HRS) and the Hyper-stability Signature Sensitive (HSS), as complementary metrics to the average AUC that should bring confidence in the choice for the best classification algorithm. To emphasize the importance of these scores, we compared 15 different Random Forest implementations. Our findings show that the Random Forest implementation should be chosen according to the data at hand and the classification question being evaluated. No Random Forest implementation can be used universally for any classification and on any dataset. Each of them should be tested for their average AUC performance and AUC-derived stability, prior to analysis.

Indexed as

AlgorithmsBiomarkersComputational BiologyArea Under CurveHumansRandom ForestReproducibility of ResultsBiomarkersAUC stabilitybiomarkercancer diagnosis signatureRandom Forest reproducibilityshort signature discovery

Identifiers

PMID40641044
PMCPMC12245662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.